Alphyn secures $25m in Series B for trial of Zabalafin Hydrogel
Alphyn Biologics has completed $25m in a Series B funding round to support the global Phase IIb trial of its …
Post
-
-
Anova introduces AI patient matching solution for clinical trials
Anova Enterprises has launched the AnovaOS software-as-a-service (SaaS) platform, a new AI-based patient matching solution for clinical trials. The solution is …
-
Rezolute stock crashes after sole pipeline candidate fails Phase III
Rezolute’s stock has crashed after its only pipeline product flopped in a Phase III trial. In the sunRIZE trial (NCT06208215), ersodetug, …
-
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4 trial, …
-
AI takes charge of data, but challenges linger
For years, one of the biggest barriers to effectively implementing artificial intelligence (AI) into clinical trial data management has been …
-
Rezolute stock crashes after sole pipeline candidate fails Phase III
Rezolute’s stock has crashed after its only pipeline product flopped in a Phase III trial. In the sunRIZE trial (NCT06208215), ersodetug, …
-
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4 trial, …
-
AI takes charge of data, but challenges linger
For years, one of the biggest barriers to effectively implementing artificial intelligence (AI) into clinical trial data management has been …
-
FDA grants clearance to Prilenia and Ferrer’s Phase III ALS therapy trial
The US Food and Drug Administration (FDA) has granted clearance to Prilenia Therapeutics and Ferrer to commence a Phase III …
-
Lindus Health and Quotient Sciences to support sponsors with trial recruitment
Lindus Health and Quotient Sciences have entered a strategic collaboration to support biotech and pharmaceutical sponsors with subject recruitment for …
-
ASH 2025: J&J’s Tecvayli + Darzalex set to redefine early relapsed MM
At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, Florida, from 6 to 9 December, updated …
-
GRI Bio’s tazarotene achieves Phase IIa IPF success
GRI Bio’s lead candidate, tazarotene, has exhibited disease-modifying potential in a mid-stage study in idiopathic pulmonary fibrosis (IPF). In the US-based …
-
APAC’s rising stars beyond China
While China continues to dominate clinical trial activity across Asia-Pacific (APAC) and globally, other countries are rapidly emerging as significant …
-
UK MHRA clears Ensoma’s EN-374 trial application for X-CGD
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared Ensoma’s clinical trial authorisation (CTA) application for its in …
-
EpilepsyGTx secures $33m to progress FRE therapy through Phase I/IIa trials
Biotechnology firm EpilepsyGTx has secured $33m in a Series A funding round to progress its adeno-associated viral (AAV) gene therapy, …
